Despite the intention of international psoriasis treatment guidelines to cover all patients globally, disparities persist in the availability and accessibility of adequate therapy in many countries. The Global Healthcare Study on Psoriasis (GHSP) aims to study patient characteristics, disease impact, treatment accessibility and healthcare systems worldwide. This study provides a description and data analysis of 22 countries.

The GHSP cohort was initiated in 2020, and the number of recruiting centres has gradually grown. Participants are recruited by dermatologists at reference centres worldwide. Data are collected using a standardised assessment questionnaire comprising 88 items, administered by trained experts.

By 26 October 2024, cross-sectional data had been collected from 3950 psoriasis patients at 130 reference centres in 22 countries on six continents. The majority (55.7%) of patients were male, and the median (IQR) body mass index was 26.5 (23.7–30.1) kg/m². The median (IQR) Psoriasis Area and Severity Index was 5.0 (2.0–11.4), and median (IQR) Dermatology Life Quality Index was 7.0 (2.0–14.0). Psoriatic arthritis was present in 20.2% of the patients and nail psoriasis in 36.7%. Additionally, 16.5% of patients were current smokers, and 26.4% reported regular alcohol consumption.

By identifying inequalities, special patient populations and country-specific differences, the GHSP will guide the development of strategies to enhance psoriasis care on a global level. Future directions include expanding the study to additional countries and sites worldwide, while transitioning into a long-term global registry of skin diseases, including atopic dermatitis and hidradenitis suppurativa, termed ‘Global Healthcare Registry on Skin Diseases’.

Narrative interventions elicit personal stories from participants to impact outcome(s). The process of organising a troublesome experience into a cohesive story may benefit individuals dealing with a variety of complex medical conditions and psychosocial stressors. A better understanding of prior work is a critical step to guide further development, refinement and expansion of this under-recognised therapeutic modality for new populations.

This scoping review will follow recommendations of the Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews to map and summarise the content and context of brief narrative interventions intended for individuals with chronic illness and/or psychosocial distress. Inclusion criteria are records describing brief (≤4 discrete session) interventions eliciting personal stories with the intent of impacting patient-centred outcomes (eg, depression, quality of life) delivered in any context. Participants will be adults (≥18 years old) living with chronic medical or psychiatric conditions (eg, metastatic cancer, chronic pain) or psychosocial distress (eg, grief, loneliness). Studies whose focus is not direct participant benefit or studies conducted in populations without evident illness or psychosocial stressors will be excluded. An initial search of PubMed (MEDLINE) identified sentinel articles; a comprehensive strategy was developed with the assistance of a librarian for systematically searching PubMed (MEDLINE), PsycInfo (EBSCOhost), CINAHL (EBSCOhost) and Embase (Ovid). Bibliographies of relevant articles will also be examined. Two independent reviewers will screen articles; disagreements will be discussed at regular meetings. U-M GPT, an artificial intelligence-powered institutional large language model, will perform initial data abstraction with a human reviewer verifying accuracy. Findings will be qualitatively summarised according to the three research questions, presented in tabular format, and described narratively.

As data will be obtained only from secondary sources, no ethics approval will be sought. Findings will be disseminated via the scoping review Open Science Framework (OSF) project site and submitted for peer review. Results will elucidate promising areas for future research, including narrative intervention development and refinement; these findings will guide expansion into new populations.

https://osf.io/85hjd/

The aims of this study were (1) to develop and validate the interactive CLAIM Test (iCLAIM Test) to measure children’s ability to assess claims about treatment effects and make informed health choices and (2) to measure this ability in Spanish primary school children using the developed test.

We followed a multistep process including (1) definition of the test scope, (2) selection of the questions, (3) translation process, (4) design and development of the online test, (5) external review with experts, (6) user-test with children and (7) cross-sectional validation study with Rasch analysis.

Spanish primary schools.

Twelve experts (75% women) participated in the review, 11 children (45% girls) participated in the user-test and 480 Spanish primary school children (46.5% girls) from fourth to sixth grades (9–12 years old) participated in the cross-sectional validation study.

The iCLAIM Test is an online, interactive and user-friendly test in Spanish that measures children’s ability to understand and apply key concepts of the informed health choices (IHC) Project when assessing claims about treatment effects and making IHCs. The test includes 30 questions: six demographic questions and 24 questions from the Claim Evaluation Tools item bank. Less than 40% of the students who participated in the cross-sectional validation study showed basic knowledge of the IHC Key Concepts and how to apply them, and less than 4% showed a clear knowledge. The test showed a good fit to the Rasch model and was acceptable to the target audience.

The iCLAIM Test is the first instrument validated for measuring children’s ability to assess treatment claims in Spain. In the future, we can tailor IHC education interventions and improve critical thinking skills about the health of Spanish children.

Alcohol use disorder (AUD) is a prevalent, chronic condition generating considerable global morbidity, mortality and socioeconomic burden. Despite the availability of established pharmacotherapies, overall treatment uptake remains low and effect sizes are moderate at best. Emerging evidence highlights substantial differences in treatment response between sexes and genders, yet these factors are rarely systematically considered in clinical trials or routine care. Existing reviews have limited scope and often exclude gender-diverse populations. This project aims to (1) Synthesise evidence on gender- and sex-specific efficacy, safety and adherence in AUD pharmacotherapies, (2) Evaluate the consideration of sex and gender beyond binary classifications in existing research and (3) Develop recommendations for gender- and sex-sensitive treatment strategies.

A systematic review and meta-analysis will be conducted using (PubMed, Web of Science, Scopus, Google Scholar, German Clinical Trials Register and ClinicalTrials.gov). We will include randomised controlled trials of pharmacotherapies for AUD with a minimum treatment duration of 4 weeks, reporting gender-specific and/or sex-specific results. The literature search will cover studies published up to October 2025, with inclusion restricted to articles published in English or German, regardless of setting. Two reviewers will independently screen records and assess risk of bias (Cochrane RoB), with evidence certainty evaluated using Grading of Recommendations Assessment, Development and Evaluation and aligned to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 and Sex and Gender Equity in Research guidelines.

Ethics approval is not required as only data from already completed studies and supplementary information directly provided by study authors are used. Findings and recommendations will be disseminated in peer-reviewed journals and presented at conferences and workshops.

CRD420251079160.

Alcohol dependence (AD) is highly prevalent and has severe consequences on health and quality of life. However, the efficacy of approved pharmacotherapies such as naltrexone (NTX) remains limited, highlighting the need for novel pharmacotherapeutic approaches. Cannabidiol (CBD) is a promising candidate, which has shown potential to reduce craving and alcohol use by modulating brain circuits involved in craving and addiction. Preclinical studies suggest that CBD may enhance NTX’s therapeutic effects.

This is a three-armed, randomised, double-blind, placebo-controlled parallel group, multicentre phase II clinical trial. A total of 150 patients with AD will be randomised (1:1:1) to receive either 800 mg or 1200 mg CBD plus 50 mg oral NTX or placebo plus 50 mg oral NTX for 14 days. Alcohol craving will be assessed using the Obsessive Compulsive Drinking Scale (OCDS-G) where the primary endpoint is the change from baseline to the end of treatment. Secondary outcomes include craving during the entire study, quality of life, depressive symptoms, anxiety, patient-reported outcomes, neural brain activation, CBD plasma levels, time to relapse, alcohol use and treatment safety. For the comparison of each experimental group to the control group, a strata-adjusted (centre and baseline OCDS-G) van Elteren test is applied with adjustment for multiple testing by Bonferroni-Holm.

The trial has been approved by the Ethics Committee and the competent authority (ID: B_03510). All participants will provide written informed consent. An independent Data and Safety Monitoring Board will monitor safety. This trial complies with national and international regulations.

NCT06845124; EU Trial Number: 2024-518164-12-00.

This study aims to assess the association of multimorbidity with capacity impairment in the Chilean population.

Cross-sectional study.

We analysed data from the National Health Survey performed in Chile in 2016 and 2017.

Persons aged 15 years and over were selected using a random, stratified and multistage sampling by clusters in all 15 geographical regions of the country.

We consider the WHO’s definition of multimorbidity as the coexistence of two or more chronic conditions in the same person. For capacity impairment, the survey included 24 items in eight dimensions that represent functioning as a reflection of the overall health experience perceived by an individual with a health condition and interacting with the environment.

The 2016–2017 ENS (Encuesta Nacional de Salud) included 6233 participants (mean age 48.9±19.3, and 62% women). There is an association between impairment of capacity and being a woman (OR=1.62; 95% CI 1.37 to 1.92) and between being under 45 years old and conserved capacity (OR=0.8, 95% CI 0.64 to 0.99). The predictive model determined that women classified with five or more chronic conditions of 80 years and over and with less than 8 years of formal education reach the highest probability of having any impairment of capacity.

Multimorbidity is associated with impaired capacity in the adult population in Chile, and these public health problems are present at early ages and have a greater impact on women.